Evidence map›Paper›PMID 38515456›Full record

ReviewPathology oncology research : POR2024

mTOR hyperactivity and

Dániel Sztankovics, Dorottya Moldvai, Gábor Petővári, Titanilla Dankó, Fatime Szalai, Risa Miyaura, Viktória Varga, Noémi Nagy, Gergő Papp, Judit Pápay and 2 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pathology oncology research : POR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Dániel SztankovicsDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Dorottya MoldvaiDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Gábor PetőváriDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Titanilla DankóDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Fatime SzalaiDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Risa MiyauraDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Viktória VargaDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Noémi NagyDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Gergő PappDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Judit PápayDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Ildikó Krencz *Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Anna Sebestyén *Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
HUN-REN Institute of Experimental Medicine · HUSemmelweis University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing knowledge of molecular alterations in malignancies, including mutations and regulatory failures in the mTOR (mechanistic target of rapamycin) signaling pathway, highlights the importance of mTOR hyperactivity as a validated target in common and rare malignancies. This review summarises recent findings on the characterization and prognostic role of mTOR kinase complexes (mTORC1 and mTORC2) activity regarding differences in their function, structure, regulatory mechanisms, and inhibitor sensitivity. We have recently identified new tumor types with

Indexed as

Lung NeoplasmsTOR Serine-Threonine KinasesHumansMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2Rapamycin-Insensitive Companion of mTOR ProteinSirolimusTranscription FactorsMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2Rapamycin-Insensitive Companion of mTOR ProteinRICTOR protein, humanSirolimusTOR Serine-Threonine KinasesTranscription FactorsmalignanciesmTORmTORC2 hyperactivityRICTOR amplificationRictor overexpression

Identifiers

PMID38515456
PMCPMC10954904
OpenAlexW4392559301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.